Zydus Lifesciences (BOM:532321) said Tuesday that it has filed a marketing application with the U.S. and Canadian health authorities for FYB206, the proposed copycat version of the popular cancer therapy, Keytruda, developed in collaboration with German biosimilar firm Formycon.
The company said it expects to hear U.S. Food and Drug Administration's decision on the application in the third quarter next year, but did not provide a timeline for when it would hear back from Health Canada.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.